How to Reverse Insulin Resistance: UK Guide

How to reverse insulin resistance is a question that matters for millions of people in the UK living with prediabetes, type 2 diabetes or metabolic risk. Insulin resistance develops when cells stop responding effectively to insulin, raising blood glucose and increasing the risk of serious long-term complications. The good news is that meaningful improvement is achievable for many people through targeted lifestyle changes, dietary adjustments and, where appropriate, medication. This article explains what insulin resistance is, what the evidence says about improving it, and when to seek medical advice.

What is insulin resistance and how does it develop?

Insulin resistance develops when cells respond less effectively to insulin, often driven by excess visceral fat, physical inactivity, poor diet, chronic stress and conditions such as PCOS. It is frequently silent early on and identified through raised fasting glucose or HbA1c.

Insulin resistance is a condition in which the body's cells respond less effectively to insulin, the hormone produced by the pancreas that allows glucose to enter cells and be used for energy. When cells become resistant, the pancreas compensates by producing more insulin, leading to elevated insulin levels in the blood. Over time, if the pancreas cannot keep up with demand, blood glucose levels rise, increasing the risk of type 2 diabetes and cardiovascular disease.

Insulin resistance develops gradually and is influenced by a combination of genetic, metabolic and lifestyle factors. Excess body fat, particularly visceral fat stored around the abdomen, is strongly associated with reduced insulin sensitivity. This is partly because adipose tissue releases inflammatory signals and free fatty acids that interfere with insulin signalling pathways in muscle, liver and fat cells.

Several other factors contribute to its development:

• Physical inactivity, which reduces the muscles' capacity to take up glucose

• Poor dietary patterns, particularly diets high in refined carbohydrates and ultra-processed foods

• Chronic sleep deprivation and stress, which raise cortisol levels and impair glucose regulation

• Certain medical conditions, including polycystic ovary syndrome (PCOS) and metabolic dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease)

Insulin resistance is often silent in its early stages, with no obvious symptoms. It is frequently identified through blood tests that suggest dysglycaemia or raised cardio-metabolic risk, such as elevated fasting glucose, raised triglycerides or a high HbA1c, though these tests do not diagnose insulin resistance directly. In the UK, non-diabetic hyperglycaemia (prediabetes) is typically defined as an HbA1c of 42 to 47 mmol/mol or a fasting plasma glucose of 6.1 to 6.9 mmol/l, while a diagnosis of type 2 diabetes requires an HbA1c of 48 mmol/mol or above (or a fasting plasma glucose of 7.0 mmol/l or above) on two separate occasions in the absence of symptoms. Understanding how insulin resistance develops is the first step towards addressing it effectively.

Can you actually reverse insulin resistance, or just manage it?

Insulin resistance can be meaningfully improved, and diabetes remission (HbA1c below 48 mmol/mol for six months without medication) is achievable for some people, particularly those with shorter diabetes duration who achieve significant weight loss.

Insulin resistance can be meaningfully improved in many people, particularly when it is identified before type 2 diabetes has developed, and when sustained lifestyle changes are made. In this context, restoring insulin sensitivity to a level where blood glucose regulation returns to a normal or near-normal range without ongoing medication is a realistic goal for a significant proportion of people with prediabetes or early insulin resistance.

The evidence base for improvement is strongest for weight loss. Research consistently shows that losing even a modest proportion of body weight, particularly from the abdominal region, can substantially improve insulin sensitivity. The NHS Diabetes Prevention Programme demonstrates that structured lifestyle intervention can reduce the risk of progressing from prediabetes to type 2 diabetes by a clinically meaningful degree.^[3][4]

For people who already have established type 2 diabetes, the picture is more nuanced. Remission, broadly defined in UK clinical practice as a sustained HbA1c below 48 mmol/mol for at least six months without glucose-lowering medication, is achievable for some, particularly those who have had diabetes for a shorter duration and who achieve significant weight loss.^[1][6] However, not everyone will reach full remission, and ongoing management remains important even when improvements are substantial. The term "reversal" is not a formal clinical diagnosis; clinicians prefer "improvement in insulin sensitivity" or "diabetes remission" when describing these outcomes.

It is also worth noting that insulin resistance exists on a spectrum. Even partial improvements in insulin sensitivity carry real clinical benefits, including lower cardiovascular risk, better blood pressure control and reduced likelihood of progression to diabetes. The goal need not be perfection; meaningful, sustained improvement is both achievable and valuable.

Which lifestyle changes make the biggest difference?

Regular physical activity and sustained weight loss have the strongest evidence for improving insulin sensitivity; combining aerobic and resistance exercise offers greater benefit than either alone, alongside good sleep, stress management and smoking cessation.

Regular physical activity and sustained weight loss are the two lifestyle changes with the strongest evidence for improving insulin sensitivity. Exercise works through multiple mechanisms: it increases glucose uptake in muscle cells independently of insulin, reduces visceral fat, and improves the function of insulin signalling pathways. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training (such as weight training or bodyweight exercises) have been shown to improve insulin sensitivity, and combining both types appears to offer greater benefit than either alone.

The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity, or 75 minutes of vigorous-intensity activity, each week, alongside muscle-strengthening activities on two or more days per week.^[11][12] These targets are consistent with the levels of activity shown to benefit insulin sensitivity and cardio-metabolic health.

Weight loss, even of 5 to 10 per cent of body weight, can produce clinically significant reductions in insulin resistance, particularly when fat is lost from the liver and abdomen. The mechanism involves reduced release of inflammatory cytokines and free fatty acids from adipose tissue, which otherwise impair insulin signalling.

Beyond exercise and weight management, the following lifestyle factors also contribute meaningfully:

• Sleep quality and duration: consistently sleeping fewer than seven hours per night is associated with worsened insulin sensitivity; assessment and treatment of sleep disorders such as obstructive sleep apnoea can improve glucose regulation^[15][16]

• Stress management: chronic psychological stress raises cortisol, which promotes glucose release from the liver and reduces insulin effectiveness

• Smoking cessation: smoking is independently associated with insulin resistance and its cardiovascular consequences

• Reducing sedentary time: breaking up prolonged sitting with short bouts of movement throughout the day has been shown to improve postprandial glucose levels

Online weight-management consultations, such as those offered by Bolt Pharmacy, a GPhC-registered UK online pharmacy, can provide prescriber review and pharmacist support as part of a broader approach to metabolic health, where clinically appropriate.

Does diet alone work, or do you need medication too?

Diet alone can improve insulin sensitivity, particularly through low-calorie, low-carbohydrate or Mediterranean-style approaches, but medication such as metformin or GLP-1 receptor agonists is recommended when lifestyle changes are insufficient or cardiovascular risk is high.

Dietary change alone can produce meaningful improvements in insulin sensitivity, particularly when it leads to weight loss and reduces the metabolic burden on the pancreas and liver. However, whether diet alone is sufficient depends on the severity of insulin resistance, the presence of type 2 diabetes, and individual response to dietary intervention.

No single dietary pattern has been shown to be universally superior, but several approaches have good evidence:

• Low-calorie diets that produce significant weight loss (including very low-calorie diets of around 800 kcal per day, used under medical supervision) have been shown in trials such as DiRECT to achieve diabetes remission in some individuals^[13][14]

• Low-carbohydrate diets can reduce postprandial glucose spikes and lower insulin demand, with some evidence of benefit for HbA1c and triglycerides

• Mediterranean-style diets, rich in vegetables, legumes, whole grains, fish and olive oil, are associated with improved insulin sensitivity and cardiovascular outcomes

Medication becomes relevant when lifestyle changes alone are insufficient to achieve adequate glucose control, or when cardiovascular or renal risk is high. NICE guidance (NG28) recommends metformin as the standard first-line pharmacological treatment for type 2 diabetes.^[1][2] However, NICE also advises that an SGLT2 inhibitor should be considered as a first-line or early addition in people with established atherosclerotic cardiovascular disease, a high risk of cardiovascular disease, heart failure or chronic kidney disease, where the cardio-renal benefits of that drug class are relevant.^[1][2] The decision on which agent to start should always be made in discussion with a GP or specialist, taking into account individual clinical circumstances.

Newer drug classes, including GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists such as tirzepatide (Mounjaro), are MHRA-authorised in the UK for both type 2 diabetes and chronic weight management.^[7][8] These medicines work primarily by enhancing glucose-dependent insulin secretion, reducing glucagon, slowing gastric emptying and supporting weight loss; improvements in glycaemic control and weight are the primary measured outcomes, with any effect on insulin sensitivity largely indirect. Eligibility for licensed weight-management medicines is based on BMI thresholds and the presence of weight-related comorbidities; NHS access also depends on local Integrated Care Board (ICB) commissioning and specialist pathways. Mounjaro is one option a prescriber may consider after an online consultation with Bolt Pharmacy, and is only prescribed where clinically appropriate.

How long does it take to see real improvements in insulin sensitivity?

Improvements in insulin sensitivity can begin within one to two weeks of lifestyle changes; clinically meaningful reductions in HbA1c or fasting glucose are generally seen over three to six months of consistent effort.

Improvements in insulin sensitivity can begin within days to weeks of making consistent lifestyle changes, though the timeline varies considerably depending on the individual, the degree of insulin resistance, and the nature of the intervention. Some studies have shown measurable improvements in insulin sensitivity within one to two weeks of starting a low-calorie diet or a structured exercise programme, even before significant weight loss has occurred.

For more substantial and sustained improvements, a longer timeframe is typically needed. Clinically meaningful reductions in HbA1c or fasting glucose are generally observed over a period of three to six months when lifestyle changes are maintained consistently. The DiRECT trial, which used a structured low-calorie dietary programme, demonstrated that remission of type 2 diabetes was achievable in a proportion of participants within one year.^[13][14]

It is helpful to understand what to monitor and when:

• Fasting blood glucose and HbA1c are the primary markers used to track progress; HbA1c reflects average blood glucose over approximately three months. When management is being actively adjusted, HbA1c is typically repeated every three months; once stable, six to twelve monthly checks are usual

• Fasting insulin and HOMA-IR (a calculated measure of insulin resistance) may be used in some clinical settings, though they are not routinely measured on the NHS and have recognised limitations in primary care

• Triglycerides and HDL cholesterol often improve alongside insulin sensitivity and can serve as useful indirect markers

Progress is rarely linear. Plateaus are common, particularly with weight loss, and should not be interpreted as failure. Reassessment with a GP or diabetes nurse every three to six months allows for timely adjustment of the management plan if needed.

When should you speak to your GP about insulin resistance?

Speak to your GP if you have risk factors for type 2 diabetes, an HbA1c of 42 to 47 mmol/mol, or symptoms such as increased thirst, fatigue or darkened skin patches; early identification allows timely intervention before the condition progresses.

You should speak to your GP about insulin resistance if you have risk factors such as a BMI above 25 kg/m² (or above 23 kg/m² if you are of South Asian, Chinese, Black African or Black Caribbean heritage), a family history of type 2 diabetes, PCOS, a history of gestational diabetes, or if you have been told your blood glucose or HbA1c is in the non-diabetic hyperglycaemia range (HbA1c 42 to 47 mmol/mol, or fasting plasma glucose 6.1 to 6.9 mmol/l). Early identification allows for timely intervention before the condition progresses. Validated UK risk tools such as QDiabetes are available online and can help you assess whether it is worth seeking a test before contacting your GP.

You should also contact your GP if you notice symptoms that may suggest worsening glucose regulation, including:

• Increased thirst or frequent urination, which can indicate rising blood glucose levels

• Unexplained fatigue or difficulty concentrating, particularly after meals

• Darkened skin patches (acanthosis nigricans) around the neck, armpits or groin, which are a recognised skin sign of insulin resistance

• Unintended weight gain, particularly around the abdomen, despite no obvious change in diet or activity

• Unintentional weight loss, recurrent infections (such as thrush or urinary tract infections), blurred vision or slow-healing wounds, which can indicate that blood glucose is already significantly elevated

If you are already managing prediabetes or type 2 diabetes and your blood glucose control is deteriorating despite lifestyle efforts, your GP can review whether medication or referral to a specialist diabetes service is appropriate. NICE guidance supports referral to the NHS Diabetes Prevention Programme for people identified with non-diabetic hyperglycaemia.^[3][4]

For urgent concerns, such as symptoms of very high blood glucose including severe thirst, vomiting or confusion, contact NHS 111 for advice. If you are unwell and unable to manage, attend your nearest A&E or call 999. Suspected adverse effects of any medication used to manage insulin resistance can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. Type 2 diabetes in adults: management (NG28).
2. Initial medicines | Type 2 diabetes in adults: management (NG28).
3. Type 2 diabetes: prevention in people at high risk (PH38).
4. Type 2 diabetes: prevention in people at high risk | Recommendations (PH38).
5. Type 2 diabetes in adults | Quality standards (QS209) – Quality statement 1: Preventing type 2 diabetes.
6. Type 2 diabetes | Treatment summaries – BNF – NICE.
7. Tirzepatide | Drugs – BNF – NICE.
8. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
9. Mounjaro | European Medicines Agency (EMA).
10. Population level impact of the NHS Diabetes Prevention Programme. Lancet Regional Health – Europe.
11. UK Chief Medical Officers' physical activity guidelines.
12. Physical activity guidelines for adults aged 19 to 64.
13. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lean MEJ et al..
14. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT). Lean MEJ et al..
15. Does Insufficient Sleep Increase the Risk of Developing Insulin Resistance: A Systematic Review..
16. Effects of sleep manipulation on markers of insulin sensitivity: A systematic review and meta-analysis of randomized controlled trials..
17. Effects of concurrent training sequence on cardiometabolic risk factors in patients with type 2 diabetes: a systematic review and network meta-analysis..
18. Appendix A1: Summary of evidence from surveillance (NG246) – BMI thresholds for South Asian and other ethnic minority groups.

Frequently Asked Questions